FORUS Therapeutics is thrilled to announce Weihao Tang as Senior Product Manager. Weihao brings more than 10 years of experience across the pharmaceutical and clinical diagnostics industries, combining a strong scientific foundation with broad commercial expertise....

FORUS Therapeutics is thrilled to announce Marie-Eve Caron as Associate Director, Sales. Marie-Eve brings more than 20 years of pharmaceutical experience, including over 13 years in specialty care across immunology and hematology/oncology. Throughout her career, she...

(OAKVILLE, Ontario) 6 juillet 2026 ­– FORUS Therapeutics Inc (« FORUS »), une filiale en propriété exclusive de PharmaEssentia Corp, a le plaisir d’annoncer qu’elle a reçu un avis de conformité (AC) autorisant BESREMIMD (ropeginterféron alfa-2b) pour le traitement des...

(OAKVILLE, Ontario) June 11, 2026 ­– FORUS Therapeutics Inc (“FORUS”) is pleased to announce that it has been acquired by PharmaEssentia Corporation, a global biopharmaceutical company focused on developing innovative therapies for hematology, oncology, and...

We are pleased to announce that Marie-Josèphe Champagne has returned to FORUS as Senior Medical Science Liaison (MSL) for Quebec and Atlantic. Marie-Josèphe brings extensive experience from her recent role as National MSL Manager for Hematology, along with more than a...

FORUS Therapeutics Inc. a le plaisir d’annoncer que XPOVIO® (sélinexor) bénéficie désormais d’un financement public au Québec depuis le 6 novembre. Pour plus de détails sur les critères, consultez les liens ci-dessous : Liste des médicaments - Établissement - en...

FORUS Therapeutics is thrilled to welcome Lisa Kolomaya as Therapeutic Area Manager, Hematology/Oncology, AB/SK. Lisa is a results-driven life sciences professional with extensive expertise in both oncology and hematology. Guided by a strategic mindset and passion for...

FORUS Therapeutics is thrilled to welcome Erin Webb as Therapeutic Area Manager, Hematology/Oncology, SW ON. Erin began her career as a physician assistant in the US, caring for patients with both benign and malignant hematologic conditions as well as managing...

FORUS Therapeutics a le plaisir d’annoncer que BESREMiMD (ropeginterféron alfa-2b-njft) autorisé aux É.-U. est maintenant disponible au Canada, par l’entremise d’une importation exceptionnelle. Veuillez noter que l’ingrédient actif de BESREMiMD, le ropeginterféron...

FORUS Therapeutics Inc. et PharmaEssentia Corporation ont conclu un accord de licence exclusif pour l’enregistrement et la commercialisation de BESREMi® (ropeginterféron alfa-2b) pour le traitement de la polycythémie vraie (PV) au Canada. Selon les termes de l’accord,...

FORUS Therapeutics is thrilled to welcome Karen Winkworth as Therapeutic Area Manager, Hematology/Oncology, GTA. Karen brings with her a proven track record of delivering superior value across therapeutic areas - including over 15 years in hematology and oncology....

FORUS Therapeutics is delighted to welcome Chris Mitton as Therapeutic Area Manager, Hematology/Oncology, Atlantic Canada. Chris joins FORUS with over 30 years experience as a pharmaceutical professional with extensive expertise across various therapeutic areas,...